Myriad Genetics Inc (MYGN) - Net Assets
Based on the latest financial reports, Myriad Genetics Inc (MYGN) has net assets worth $368.00 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($706.60 Million) and total liabilities ($338.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Myriad Genetics Inc (MYGN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $368.00 Million |
| % of Total Assets | 52.08% |
| Annual Growth Rate | 5.68% |
| 5-Year Change | -61.98% |
| 10-Year Change | -50.81% |
| Growth Volatility | 28.48 |
Myriad Genetics Inc - Net Assets Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's net assets have evolved over time, based on quarterly financial data. Also explore MYGN current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Myriad Genetics Inc (1995–2025)
The table below shows the annual net assets of Myriad Genetics Inc from 1995 to 2025. For live valuation and market cap data, see Myriad Genetics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $368.00 Million | -47.51% |
| 2024-12-31 | $701.10 Million | -10.48% |
| 2023-12-31 | $783.20 Million | -11.58% |
| 2022-12-31 | $885.80 Million | -8.47% |
| 2021-12-31 | $967.80 Million | +9.85% |
| 2020-12-31 | $881.00 Million | -19.09% |
| 2019-12-31 | $1.09 Billion | +12.85% |
| 2018-12-31 | $964.90 Million | +24.06% |
| 2017-12-31 | $777.80 Million | +3.97% |
| 2016-12-31 | $748.10 Million | +12.99% |
| 2015-12-31 | $662.10 Million | -7.91% |
| 2014-12-31 | $719.00 Million | -1.32% |
| 2013-12-31 | $728.59 Million | +14.62% |
| 2012-12-31 | $635.66 Million | +12.15% |
| 2011-12-31 | $566.79 Million | +1.65% |
| 2010-12-31 | $557.58 Million | +28.41% |
| 2009-12-31 | $434.22 Million | +2.01% |
| 2008-12-31 | $425.65 Million | +25.06% |
| 2007-12-31 | $340.36 Million | +36.26% |
| 2006-12-31 | $249.78 Million | +84.11% |
| 2005-12-31 | $135.67 Million | -21.70% |
| 2004-12-31 | $173.28 Million | +5.99% |
| 2003-12-31 | $163.49 Million | +26.86% |
| 2002-12-31 | $128.87 Million | -7.66% |
| 2001-12-31 | $139.56 Million | +79.60% |
| 2000-12-31 | $77.71 Million | +61.22% |
| 1999-12-31 | $48.20 Million | -16.17% |
| 1998-12-31 | $57.50 Million | -13.14% |
| 1997-12-31 | $66.20 Million | -5.70% |
| 1995-12-31 | $70.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Myriad Genetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 110780000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $900.00K | 0.24% |
| Other Comprehensive Income | $800.00K | 0.22% |
| Other Components | $1.49 Billion | 404.62% |
| Total Equity | $368.00 Million | 100.00% |
Myriad Genetics Inc Competitors by Market Cap
The table below lists competitors of Myriad Genetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cohen Dev
TA:CDEV
|
$360.35 Million |
|
Cambi ASA
OL:CAMBI
|
$360.36 Million |
|
Civeo Corp
NYSE:CVEO
|
$360.36 Million |
|
Magnetic Resources NL
AU:MAUCA
|
$360.39 Million |
|
Dine Brands Global Inc
NYSE:DIN
|
$360.01 Million |
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
$359.97 Million |
|
Guangdong Guoli Sci&Tech Co Ltd Class A
SHE:300716
|
$359.90 Million |
|
Tonnellerie Francois Freres SA
PA:TFF
|
$359.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Myriad Genetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 701,100,000 to 368,000,000, a change of -333,100,000 (-47.5%).
- Net loss of 365,900,000 reduced equity.
- Other comprehensive income increased equity by 1,600,000.
- Other factors increased equity by 31,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-365.90 Million | -99.43% |
| Other Comprehensive Income | $1.60 Million | +0.43% |
| Other Changes | $31.20 Million | +8.48% |
| Total Change | $- | -47.51% |
Book Value vs Market Value Analysis
This analysis compares Myriad Genetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.66x to 0.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $2.32 | $3.85 | x |
| 1997-12-31 | $1.86 | $3.85 | x |
| 1998-12-31 | $1.54 | $3.85 | x |
| 1999-12-31 | $1.28 | $3.85 | x |
| 2000-12-31 | $1.92 | $3.85 | x |
| 2001-12-31 | $3.06 | $3.85 | x |
| 2002-12-31 | $2.72 | $3.85 | x |
| 2003-12-31 | $3.18 | $3.85 | x |
| 2004-12-31 | $3.17 | $3.85 | x |
| 2005-12-31 | $2.21 | $3.85 | x |
| 2006-12-31 | $3.44 | $3.85 | x |
| 2007-12-31 | $4.15 | $3.85 | x |
| 2008-12-31 | $4.56 | $3.85 | x |
| 2009-12-31 | $4.41 | $3.85 | x |
| 2010-12-31 | $5.62 | $3.85 | x |
| 2011-12-31 | $6.18 | $3.85 | x |
| 2012-12-31 | $7.35 | $3.85 | x |
| 2013-12-31 | $8.74 | $3.85 | x |
| 2014-12-31 | $9.20 | $3.85 | x |
| 2015-12-31 | $8.89 | $3.85 | x |
| 2016-12-31 | $10.19 | $3.85 | x |
| 2017-12-31 | $11.31 | $3.85 | x |
| 2018-12-31 | $13.40 | $3.85 | x |
| 2019-12-31 | $14.33 | $3.85 | x |
| 2020-12-31 | $11.78 | $3.85 | x |
| 2021-12-31 | $12.41 | $3.85 | x |
| 2022-12-31 | $10.99 | $3.85 | x |
| 2023-12-31 | $9.46 | $3.85 | x |
| 2024-12-31 | $7.74 | $3.85 | x |
| 2025-12-31 | $3.94 | $3.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Myriad Genetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.38%
- • Asset Turnover: 1.17x
- • Equity Multiplier: 1.92x
- Recent ROE (-99.43%) is below the historical average (-6.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -8.40% | -89.39% | 0.08x | 1.13x | $-12.92 Million |
| 1997 | -13.90% | -60.53% | 0.20x | 1.15x | $-15.82 Million |
| 1998 | -17.04% | -42.24% | 0.34x | 1.17x | $-15.55 Million |
| 1999 | -20.75% | -39.53% | 0.47x | 1.11x | $-14.82 Million |
| 2000 | -11.22% | -25.64% | 0.32x | 1.37x | $-16.49 Million |
| 2001 | -5.14% | -15.89% | 0.26x | 1.23x | $-21.13 Million |
| 2002 | -10.86% | -25.98% | 0.34x | 1.22x | $-26.88 Million |
| 2003 | -15.18% | -38.60% | 0.35x | 1.12x | $-41.17 Million |
| 2004 | -23.44% | -71.71% | 0.30x | 1.09x | $-57.95 Million |
| 2005 | -29.47% | -48.51% | 0.52x | 1.17x | $-53.55 Million |
| 2006 | -15.29% | -33.42% | 0.41x | 1.11x | $-63.17 Million |
| 2007 | -10.27% | -22.25% | 0.42x | 1.09x | $-69.00 Million |
| 2008 | 11.24% | 14.34% | 0.67x | 1.17x | $5.28 Million |
| 2009 | 19.49% | 25.91% | 0.70x | 1.07x | $41.19 Million |
| 2010 | 27.31% | 42.00% | 0.61x | 1.07x | $96.54 Million |
| 2011 | 17.77% | 25.05% | 0.66x | 1.08x | $44.03 Million |
| 2012 | 17.64% | 22.61% | 0.72x | 1.09x | $48.59 Million |
| 2013 | 20.19% | 24.00% | 0.76x | 1.10x | $74.28 Million |
| 2014 | 24.51% | 22.64% | 0.94x | 1.15x | $104.33 Million |
| 2015 | 12.11% | 11.09% | 0.94x | 1.16x | $13.99 Million |
| 2016 | 16.75% | 16.62% | 0.86x | 1.18x | $50.49 Million |
| 2017 | 2.80% | 2.83% | 0.63x | 1.57x | $-56.02 Million |
| 2018 | 13.58% | 16.96% | 0.66x | 1.22x | $34.51 Million |
| 2019 | 0.42% | 0.54% | 0.54x | 1.44x | $-104.29 Million |
| 2020 | -25.39% | -40.16% | 0.39x | 1.61x | $-311.80 Million |
| 2021 | -2.81% | -3.94% | 0.52x | 1.36x | $-123.98 Million |
| 2022 | -12.64% | -16.51% | 0.57x | 1.35x | $-200.58 Million |
| 2023 | -33.62% | -34.96% | 0.66x | 1.46x | $-341.62 Million |
| 2024 | -18.16% | -15.20% | 0.82x | 1.47x | $-197.41 Million |
| 2025 | -99.43% | -44.38% | 1.17x | 1.92x | $-402.70 Million |
Industry Comparison
This section compares Myriad Genetics Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $614,679,509
- Average return on equity (ROE) among peers: -91.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Myriad Genetics Inc (MYGN) | $368.00 Million | -8.40% | 0.92x | $360.01 Million |
| Agilent Technologies Inc (A) | $5.90 Billion | 21.85% | 1.01x | $32.57 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $6.51 Million |
| Applied DNA Sciences Inc (APDN) | $-995.38K | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.61 Million | -317.61% | 3.51x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $7.42 Million |
| Biocept Inc. (BIOCQ) | $23.69 Million | -75.16% | 1.00x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.50 Billion |
| Burning Rock Biotech Ltd (BNR) | $168.49 Million | -77.91% | 1.38x | $126.13 Million |
| CareDx Inc (CDNA) | $-5.95 Million | 0.00% | 0.00x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more